This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Psoriasis  • Phototherapy  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic

Arch Dermatol. 2002;138:686-688.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE ABILITY to create custom-made drugs that target specific cell receptors or specific cytokines is heralding a new era in the treatment of inflammatory diseases. This is particularly relevant for psoriasis because the agents that have been developed block specific steps in the pathogenesis of this disease. In this issue of the ARCHIVES, Singri and coauthors¹ present an excellent mechanism-oriented description of the new biologic therapies emerging for treatment of psoriasis.

Recognizing that the skin changes in psoriasis are easily evaluated, many of the pharmaceutical companies have chosen to test their drugs in psoriasis at an early stage in the evolution of these therapies. Before enthusiastically embracing these exciting new therapeutic modalities, an important question must be asked: Do we really need more psoriasis treatments?

THE IDEAL PSORIASIS THERAPY

Over the past 25 years, probably more treatments have been developed for psoriasis than for any other skin disorder. Not even counting the many topical . . . [Full Text of this Article]

SAFETY AND EFFICACY OF NEW BIOLOGIC AGENTS FOR PSORIASIS

THE IDEAL PATIENT

RELATED ARTICLE

Biologic Therapy for Psoriasis: The New Therapeutic Frontier
Prashant Singri, Dennis P. West, and Kenneth B. Gordon
Arch Dermatol. 2002;138(5):657-663.
ABSTRACT | FULL TEXT